154 related articles for article (PubMed ID: 37534789)
1. Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study.
D'Amico E; Zanghì A; Fantozzi R; Centonze D; Avolio C
Curr Neuropharmacol; 2023; 21(12):2563-2566. PubMed ID: 37534789
[TBL] [Abstract][Full Text] [Related]
2. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
[TBL] [Abstract][Full Text] [Related]
3. Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination.
Faissner S; Heitmann N; Plaza-Sirvent C; Trendelenburg P; Ceylan U; Motte J; Bessen C; Urlaub D; Watzl C; Overheu O; Reinacher-Schick A; Hellwig K; Pfaender S; Schmitz I; Gold R
Front Immunol; 2022; 13():980526. PubMed ID: 36119053
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.
Yu H; Graham G; David OJ; Kahn JM; Savelieva M; Pigeolet E; Das Gupta A; Pingili R; Willi R; Ramanathan K; Kieseier BC; Häring DA; Bagger M; Soelberg Sørensen P
CNS Drugs; 2022 Mar; 36(3):283-300. PubMed ID: 35233753
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
Coyle PK; Gorritz M; Wade RL; Zhou Z; Khalid S; Maiese EM; Deshpande C; Shao QS
Mult Scler Relat Disord; 2023 Oct; 78():104881. PubMed ID: 37556938
[TBL] [Abstract][Full Text] [Related]
6. Ofatumumab for relapsing forms of multiple sclerosis.
Gajofatto A; Orlandi R
Drugs Today (Barc); 2022 Jan; 58(1):9-21. PubMed ID: 35107090
[TBL] [Abstract][Full Text] [Related]
7. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
Kira JI; Nakahara J; Sazonov DV; Kurosawa T; Tsumiyama I; Willi R; Zalesak M; Pingili R; Häring DA; Ramanathan K; Kieseier BC; Merschhemke M; Su W; Saida T
Mult Scler; 2022 Jul; 28(8):1229-1238. PubMed ID: 34787005
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis.
von Essen MR; Hansen RH; Højgaard C; Ammitzbøll C; Wiendl H; Sellebjerg F
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35672145
[TBL] [Abstract][Full Text] [Related]
9. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Bar-Or A; Wiendl H; Montalban X; Alvarez E; Davydovskaya M; Delgado SR; Evdoshenko EP; Giedraitiene N; Gross-Paju K; Haldre S; Herrman CE; Izquierdo G; Karelis G; Leutmezer F; Mares M; Meca-Lallana JE; Mickeviciene D; Nicholas J; Robertson DS; Sazonov DV; Sharlin K; Sundaram B; Totolyan N; Vachova M; Valis M; Bagger M; Häring DA; Ludwig I; Willi R; Zalesak M; Su W; Merschhemke M; Fox EJ
Mult Scler; 2022 May; 28(6):910-924. PubMed ID: 34605319
[TBL] [Abstract][Full Text] [Related]
10. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
Pukoli D; Vécsei L
Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
[TBL] [Abstract][Full Text] [Related]
11. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis.
Dalla Costa G; Leocani L; Comi G
Expert Rev Clin Immunol; 2022 Feb; 18(2):105-114. PubMed ID: 35107057
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
J Comp Eff Res; 2020 Dec; 9(18):1255-1274. PubMed ID: 33090003
[No Abstract] [Full Text] [Related]
14. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.
Saidha S; Bell J; Harold S; Belisario JM; Hawe E; Shao Q; Wyse K; Maiese EM
Neurol Sci; 2023 May; 44(5):1515-1532. PubMed ID: 36648561
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N
J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139
[TBL] [Abstract][Full Text] [Related]
16. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
[TBL] [Abstract][Full Text] [Related]
18. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.
Zappulo E; Buonomo AR; Moccia M; Pinchera B; Villari R; Petracca M; Lanzillo R; Scotto R; Carotenuto A; Viceconte G; Schiano Moriello N; Bruno L; Gentile I; Brescia Morra V
Mult Scler Relat Disord; 2022 Jul; 63():103814. PubMed ID: 35487032
[TBL] [Abstract][Full Text] [Related]
19. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L
Mult Scler; 2022 Sep; 28(10):1576-1590. PubMed ID: 35229668
[TBL] [Abstract][Full Text] [Related]
20. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
